Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | QDPR | P09417 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25930081 | 0.86 | CYP3A4 (0.45) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL25984723 | 0.85 | ESR2 (0.36) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL14230677 | 0.85 | ESR2 (0.53) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL15681401 | 0.84 | CYP3A4 (0.47) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL15725311 | 0.82 | CYP2C9 (0.49) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL3275306 | 0.81 | ESR2 (0.43) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL3275302 | 0.81 | ESR2 (0.43) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL10017626 | 0.81 | ESR2 (0.33) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL15681399 | 0.79 | HDAC2 (0.36) | ESR2ESR1CYP3A4CYP2C9APP | |
| SCHEMBL24221347 | 0.78 | PDE4A (0.32) | CYP3A4CYP2C9APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168081-B2 | Liquid-crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-01 | — | — | US | disclosed |
| US-20090309066-A1 | Mixture of polar compounds containing cyclohexane and benzene rings some of which are vinylene-linked, especially containing fluoroalkoxy groups; for electrooptical twisted nematic monitor applications | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090309066-A1 | Mixture of polar compounds containing cyclohexane and benzene rings some of which are vinylene-linked, especially containing fluoroalkoxy groups; for electrooptical twisted nematic monitor applications | VIM, CDH1, LEF1 | ESR2 1692/4885ESR1 1399/4885CYP3A4 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.